Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/39960

Title:	Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
Authors:	Leiter, Lawrence A Zamorano, José Luis Bujas-Bobanovic, Maja Louie, Michael J Lecorps, Guillaume Cannon, Christopher P Handelsman, Yehuda View more
Keywords:	cardiovascular disease clinical trial dyslipidaemia type 1 diabetes type 2 diabetes View more
Mesh:	Aged Antibodies, Monoclonal Cardiovascular Diseases Cholesterol, LDL Cohort Studies Combined Modality Therapy Diabetes Complications Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Female Follow-Up Studies Healthy Lifestyle Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hyperlipidemias Hypolipidemic Agents Injections, Subcutaneous Male Middle Aged Proprotein Convertase 9 Risk Factors Serine Proteinase Inhibitors View more
Issue Date:	2017
Citation:	Diabetes Obes Metab.2017 07;(19)7:989-996
Abstract:	This sub-analysis of the ODYSSEY COMBO II study compared the effects of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in high cardiovascular risk patients with or without diabetes mellitus (DM) receiving maximally tolerated statin therapy.
PMID:	28206704
URI:	https://hdl.handle.net/20.500.12530/39960
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC5485164.pdf		1.48 MB	Adobe PDF	View/Open